Insights of Terminalia citrina (Gaertn.) Roxb. Ex Fleming inhibiting multidrug resistant Acinetobacter baumannii
Phytomedicine Plus · 2025-08 · 5 (3) · 100840
DOI: 10.1016/j.phyplu.2025.100840 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine Plus, 2025-08. Verfasst von Nevia Longjam und 11 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Biotechnology, Indian Council of Medical Research, Ministry of Science and Technology.
Abstract (Originalsprache)
Background
The Northeast region of India is renowned for its rich biodiversity and unique flora, including many plants with unstudied medicinal properties. Terminalia citrina is a medicinal plant traditionally used to treat chronic fever, loss of appetite, diarrhoea, asthma, boils, dizziness, haemorrhoids, anaemia, eye diseases, and infections. This study highlights potential bioactive compounds of T. citrina with antimicrobial activity against sepsis-causing pathogens, specifically Acinetobacter baumannii isolates, and presents the toxicity studies conducted on an animal model.
Purpose
The study focused on validating the traditional use of medicinal plants for treating microbial infections and assessing their toxicity in an animal model.
Methods
T. citrina plant species were collected and evaluated for antimicrobial activity against sepsis causing MDR pathogens Acinetobacter baumannii, Klebsiella pneumoniae, and Escherichia coli. The bioactive metabolites were identified using liquid chromatography–mass spectrometry (LC-MS). The in-vitro cytotoxicity of the active fraction was assessed using the MTT assay on the Caco-2 cell line followed by in-vivo toxicity study in BALB/c mice.
Results
The crude extract of T. citrina, obtained using a hydroalcoholic solvent, inhibited the growth of A. baumannii isolates AB0014, AB0015, and AB0018. LC-MS analysis identified five metabolites in the EM2 subfraction of T. citrina. The MTT assay demonstrated no cytotoxic effects on the Caco-2 cell line. Treatment of A. baumannii isolate AB0014 with the EM2 subfraction of T. citrina at 2.82 mg/mL altered cellular morphology, causing cell shrinkage and growth inhibition. Acute and subacute oral toxicity studies of T. citrina (EM2) showed no signs of toxicity or behavioural changes.
Conclusion
T. citrina found in Manipur, India, exhibited antimicrobial activity on MDR A. baumannii clinical isolates. The presence of phenolic compounds -in T. citrina (EM2) may be attributed to the antimicrobial activity. The T. citrina active fraction (EM2) may be an alternative candidate for developing a new drug for managing sepsis.
Förderung
- Department of Biotechnology
- Indian Council of Medical Research
- Ministry of Science and Technology
Zitieren
APA
Longjam, N., Lourembam, R. M., Rajkumari, J., Shreekant, S., Bhattacharya, S., Kar, A., Chaudhary, S. K., Basu, S., Jena, S., Senapati, S., Mukherjee, P. K., & Devi, S. I. (2025). Insights of Terminalia citrina (Gaertn.) Roxb. Ex Fleming inhibiting multidrug resistant Acinetobacter baumannii. Phytomedicine Plus, 5(3), 100840. https://doi.org/10.1016/j.phyplu.2025.100840
Vancouver
Longjam N, Lourembam RM, Rajkumari J, Shreekant S, Bhattacharya S, Kar A, et al. Insights of Terminalia citrina (Gaertn.) Roxb. Ex Fleming inhibiting multidrug resistant Acinetobacter baumannii. Phytomedicine Plus. 2025;5(3):100840. doi:10.1016/j.phyplu.2025.100840
BibTeX
@article{Longjam2025,
author = {Longjam, Nevia and Lourembam, Romen Meitei and Rajkumari, Jobina and Shreekant, Sadokpam and Bhattacharya, Sushmita and Kar, Amit and Chaudhary, Sushil Kumar and Basu, Sulagna and Jena, Sarita and Senapati, Shantibhusan and Mukherjee, Pulok Kumar and Devi, Sarangthem Indira},
title = {Insights of Terminalia citrina (Gaertn.) Roxb. Ex Fleming inhibiting multidrug resistant Acinetobacter baumannii},
journal = {Phytomedicine Plus},
year = {2025},
volume = {5},
number = {3},
pages = {100840},
doi = {10.1016/j.phyplu.2025.100840}
}
EUVIMED